How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal – Investor’s Business Daily
Life Sciences Intellectual Property Review |
How These Gene Therapy Stocks Benefit From Novartis-AveXis Deal
Investor’s Business Daily The implications of Novartis' deal for Spark are less clear. Spark is already partnered with Novartis on gene therapy Luxturna in Europe. Investors had been optimistic about the potential for a merger between Novartis and Spark. "We think investor … Novartis to buy Avexis in $8.7 billion gene–therapy deal Novartis signs $8.7bn gene therapy deal Novartis increases presence in gene therapy with AveXis acquisition |
